NYMX Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a current update on the Company's ongoing projects. The Company recently submitted its application for Marketing Authorization Application to the Danish authorities. The application to the Danish authorities was accepted for review in February and is under review at this time. 

The Company now expects to be making a second new submission in the next 30-60 days. Further information will be provided when this milestone is reached, which is expected near-term in the 2nd quarter of this year.

Dr. Paul Averback, CEO of Nymox, said "Management is quite pleased with the substantial progress the Company has made in this first quarter of 2023. We have had our first MAA accepted for review and we are now expecting to file an additional application in a separate jurisdiction. The Company is excited about the potential."

"The addition of Chris Riley to our management team was warmly received by our shareholders. Chris has the skill set, experience and training to help the Company to maximize the benefits to shareholders of its first in class technology.  The Company's goal is to fulfill a meaningful need for countless patients who suffer from their BPH.”

We will continue to keep shareholders informed on current developments in a timely manner."

About NYMOZARFEX (TM) (Fexapotide) 

NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 BPH patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.

For more information please contact info@nymox.com or 800-936-9669.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2021, and its Quarterly Reports.

For Further Information Contact:Randall LanhamNymox Pharmaceutical Corporation1-800-93NYMOXwww.nymox.com